Ab Cellera Biologics Inc. ABCL
Institutional shares held
120 Million
233K
calls
339K
puts
Total value of holdings
$311M
$602K
calls
$876K
puts
Market Cap
$727M
285,139,008
Shares Out.
Institutional ownership
42.08%
# of Institutions
167
We take great care to ensure that the data presented and summarized in this overview for AbCellera Biologics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABCL
View all-
Baker Bros. Advisors LP New York, NY27.5MShares$70.2 Million0.89% of portfolio
-
Baillie Gifford & CO12.2MShares$31.2 Million0.03% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$27.1 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA7.93MShares$20.2 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX7.35MShares$18.7 Million6.4% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$11.6 Million0.02% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.5MShares$11.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.18MShares$10.7 Million0.33% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO4.11MShares$10.5 Million0.18% of portfolio
-
Black Rock Inc. New York, NY3.8MShares$9.7 Million0.0% of portfolio
Latest Institutional Activity in ABCL
Top Purchases
Top Sells
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Insider Transactions at ABCL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 11
2025
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
343,631
+0.61%
|
$687,262
$2.16 P/Share
|
|
Mar 10
2025
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
25,000
+12.76%
|
$50,000
$2.3 P/Share
|
|
Mar 06
2025
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
60,000
+29.13%
|
$120,000
$2.34 P/Share
|
|
Dec 04
2024
|
Thermopylae Holdings Ltd. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
286,000
-0.51%
|
-
|
|
Nov 25
2024
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+5.88%
|
$112,250
$2.7 P/Share
|
|
Sep 20
2024
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+6.25%
|
$112,250
$2.7 P/Share
|
|
Aug 29
2024
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
283,516
+0.5%
|
$567,032
$2.61 P/Share
|
|
Jun 21
2024
|
Veronique Lecault Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
83,334
+3.78%
|
$0
$0.19 P/Share
|
|
May 31
2024
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+6.67%
|
$112,250
$2.7 P/Share
|
|
Feb 26
2024
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+7.14%
|
$112,250
$2.7 P/Share
|
|
Dec 19
2023
|
Thermopylae Holdings Ltd. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
210,000
-0.37%
|
-
|
|
Nov 23
2023
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+7.69%
|
$112,250
$2.7 P/Share
|
|
Nov 08
2023
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.42%
|
$40,000
$4.46 P/Share
|
|
Nov 06
2023
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
20,000
+20.83%
|
$80,000
$4.64 P/Share
|
|
Sep 22
2023
|
Michael R Hayden Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+1.49%
|
$80,000
$4.91 P/Share
|
|
Sep 12
2023
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+0.97%
|
$100,000
$5.19 P/Share
|
|
Aug 24
2023
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+8.33%
|
$112,250
$2.7 P/Share
|
|
Aug 08
2023
|
Michael R Hayden Director |
BUY
Open market or private purchase
|
Indirect |
30,000
+2.25%
|
$150,000
$5.9 P/Share
|
|
May 26
2023
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+9.09%
|
$112,250
$2.7 P/Share
|
|
May 26
2023
|
Andrew Booth Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
14,500
+8.66%
|
$87,000
$6.85 P/Share
|
Last 12 Months Summary
Buy / Acquisition
964K
Shares
From
4
Insiders
| Exercise of conversion of derivative security | 252K shares |
|---|---|
| Open market or private purchase | 712K shares |
Sell / Disposition
286K
Shares
From
1
Insiders
| Bona fide gift | 286K shares |
|---|